Mereo BioPharma

Mereo BioPharma MREO Stock

$0.29   5.391610%
Add to favorites
Market Cap
$46.20M
LOW - HIGH [24H]
$0.27 - $0.30
VOLUME [24H]
$859.63K
P/E Ratio
0
Earnings per share
-$0.15
ISIN
US5894921072
Price   Prediction

Mereo BioPharma Price Chart

Sorry, that's all we've gotfor now...

Mereo BioPharma (MREO) stock price today is 0.29 USD on Tech Market Small (+5.39% on the day). Updated .

Mereo BioPharma MREO Financial and Trading Overview

Mereo BioPharma stock price 0.29 USD
Previous Close 0.27 USD
Open 0.27 USD
Bid 0.29 USD x 100
Ask 0.48 USD x 200
Day's Range 0.27 - 0.3 USD
52 Week Range 0.2 - 2.37 USD
Volume 688.29K USD
Avg. Volume 1.24M USD
Market Cap 46.3M USD
Beta (5Y Monthly) 0.201
PE Ratio (TTM) N/A
EPS (TTM) -0.15 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 1.95 USD

MREO Valuation Measures

Enterprise Value 18.32M USD
Trailing P/E N/A
Forward P/E -13.385095
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 57.87152
Price/Book (mrq) 1.9587837
Enterprise Value/Revenue 22.897
Enterprise Value/EBITDA -0.639

Trading Information

Mereo BioPharma Stock Price History

Beta (5Y Monthly) 0.201
52-Week Change -84.80%
S&P500 52-Week Change 10.51%
52 Week High 2.37 USD
52 Week Low 0.2 USD
50-Day Moving Average 0.31 USD
200-Day Moving Average 0.32 USD

MREO Share Statistics

Avg. Volume (3 month) 1.24M USD
Avg. Daily Volume (10-Days) 925.65K USD
Shares Outstanding 159.7M
Float 125.03M
Short Ratio 3.48
% Held by Insiders 0.74%
% Held by Institutions 34.63%
Shares Short 3.35M
Short % of Float 2.57%
Short % of Shares Outstanding 2.10%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 0%
Operating Margin (ttm) -3702.50%
Gross Margin 100.00%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -44.50%
Return on Equity (ttm) -76.62%

Income Statement

Revenue (ttm) 800K USD
Revenue Per Share (ttm) 0.005 USD
Quarterly Revenue Growth (yoy) N/A
Gross Profit (ttm) 800K USD
EBITDA -28665000 USD
Net Income Avi to Common (ttm) -26938000 USD
Diluted EPS (ttm) -0.15
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 26.1M USD
Total Cash Per Share (mrq) 0.16 USD
Total Debt (mrq) 577K USD
Total Debt/Equity (mrq) 2.43 USD
Current Ratio (mrq) 5.219
Book Value Per Share (mrq) 0.148

Cash Flow Statement

Operating Cash Flow (ttm) -22088000 USD
Levered Free Cash Flow (ttm) -11447250 USD

Profile of Mereo BioPharma

Country United States
State N/A
City London
Address One Cavendish Place
ZIP W1G 0QF
Phone 44 33 3023 7300
Website https://www.mereobiopharma.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 39

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.

Q&A For Mereo BioPharma Stock

What is a current MREO stock price?

Mereo BioPharma MREO stock price today per share is 0.29 USD.

How to purchase Mereo BioPharma stock?

You can buy MREO shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Mereo BioPharma?

The stock symbol or ticker of Mereo BioPharma is MREO.

Which industry does the Mereo BioPharma company belong to?

The Mereo BioPharma industry is Biotechnology.

How many shares does Mereo BioPharma have in circulation?

The max supply of Mereo BioPharma shares is 159.7M.

What is Mereo BioPharma Price to Earnings Ratio (PE Ratio)?

Mereo BioPharma PE Ratio is now.

What was Mereo BioPharma earnings per share over the trailing 12 months (TTM)?

Mereo BioPharma EPS is -0.15 USD over the trailing 12 months.

Which sector does the Mereo BioPharma company belong to?

The Mereo BioPharma sector is Healthcare.

Mereo BioPharma MREO included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 24429.89 USD —
+0.42
7.16B USD — 24225.3 USD — 24538.78 USD — — 7.16B USD —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
us US Tech Global Market Composite NQGM US 1839.01 USD —
+0.18
— — 1830.2 USD — 1855.92 USD — — — —
us US Tech Biotechnology NBI US 6971.7 USD —
-0.66
— — 6959.96 USD — 7076.43 USD — — — —
us US Tech Health Care IXHC US 1324.44 USD —
-0.63
— — 1322.85 USD — 1342.46 USD — — — —
$2.17T
Total marketcap
$73B
Total volume
BTC 58.91%   •   ETH 10.12%
Dominance
Select currency